Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.
Frequently asked questions
What sector does Fluicell AB (FLUI) operate in?
Fluicell AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Fluicell AB (FLUI) current stock price?
As of the latest data, Fluicell AB stock price is SEK 29.20, with a previous close of SEK 29.20.
What is Fluicell AB (FLUI) current market capitalization?
Fluicell AB market cap is approximately 40.11 million.
What is Fluicell AB (FLUI) Earnings Per Share (EPS)?
The trailing EPS is SEK 678.85.
What is Fluicell AB (FLUI) Price-to-Earnings (P/E) ratio?
Fluicell AB current P/E ratio is 0.04.
What is Fluicell AB (FLUI) EBITDA?
Fluicell AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.54 million.
Does Fluicell AB (FLUI) pay dividends?
No. Fluicell AB does not pay a dividend.
What is Fluicell AB (FLUI) beta (volatility) score?
Fluicell AB has a beta of 2.017, indicating very high volatility compared to the market.
